MONTREAL, March 18 /CNW Telbec/ - Akela Pharma Inc. (TSX: “AKL”), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that it has filed a final short form prospectus and received a receipt from Canadian regulatory authorities for an offering of up to 7,500,000 units, of which 3,750,000 units are underwritten and up to 3,750,000 units are offered on a best efforts basis at a price of $1.20 per unit for aggregate maximum proceeds of $9.0 million. The offering is being led by Jennings Capital Inc. and includes Desjardins Securities Inc. (together the “Underwriters”). The Underwriters will have the option to purchase, at $1.20, up to that number of additional units as is equal to 15% of the total number of units sold under the offering.
